Nautilus Biotech and Angel Biothechnology Sign Agreement to Manufacture Belerofon(R) (Improved Alpha Interferon) for Phase I Clinical Trials

[Guest guest]

Nautilus Biotech and Angel Biothechnology Sign Agreement to Manufacture

Belerofon® (Improved Alpha Interferon) for Phase I Clinical Trials

PARIS, France and NORTHUMBERLAND, England, December 6 /PRNewswire/ --

Nautilus Biotech a protein pharmaceuticals private company and Angel

Biotechnology a UK private company providing world class contract

manufacturing services in microbial fermentation and mammalian cell culture,

announced today that they have signed an agreement for the manufacture of

Nautilus' improved interferon alpha (Belerofon®) for Phase I clinical

development.

Nautilus has designed and developed an improved, single amino-acid

substitution, non-pegylated interferon alpha (Belerofon®) with superior

biological and pharmacological profile compared to marketed pegylated

interferon alpha. Belerofon® is a product candidate for a number of

indications including chronic HepC and cancer. Its improved profile should

support lower frequency of administration and lower dosing with higher

therapeutic efficacy.

" Nautilus is committed to advance Belerofon® into clinical

development.

This agreement for the GMP manufacture of Belerofon® shows our focus to

progressing this product candidate into clinical Phase I " , said Nautilus CEO

Vega. " We believe that in Angel we have found a partner with the

right

blend of experience and facilities to manufacture Belerofon® for the next

steps of our clinical development plan " .

" Nautilus has an impressive track record in the development of new and

improved protein therapeutics " , said Angel CEO Stuart Duncan. " We are

extremely pleased to be working with Nautilus and we are confident that

Angel

can transfer and develop Nautilus manufacturing process and associated

assays

to full cGMP compliance, taking Belerofon® to IND " .

About Belerofon

The market for alpha interferon in the treatment of chronic hepatitis C

infection only, reached $2.7 bn in 2003 and is projected to grow to $8.7 bn

by 2013 and $12.6 bn by 2018. Pegylated derivatives of alpha interferon

dominate the market based on their improved pharmacokinetics profile, which

translates into lower dosing frequency compared to native alpha interferon.

Belerofon® is a single amino acid variant of natural alpha interferon,

engineered by Nautilus, non-pegylated, non-protein fusion. Belerofon® is

an

improved product candidate with longer half-life in serum compared to native

alpha interferon. Belerofon® has a superior pharmacological profile, with

a

half-life in primates equivalent to marketed pegylated alpha interferon

products. The half-life of Belerofon® is expected to support the standard

of care of once per week dosing schedule, currently used for PEG-IFN.

About Nautilus Biotech

Nautilus is focused on improving and developing next generation protein

pharmaceuticals. Using its proprietary and unique technologies, Nautilus has

generated a pipeline of improved therapeutic protein molecules with single

amino acid substitutions; and has IP claims on 20 improved cytokines. Long

lasting interferon alpha and interferon beta, presently in preclinical

development, are Nautilus' lead molecules. Nautilus Biotech is a privately

owned, VC backed company, founded in late 1999 in the frame of the

Genopole® incubator in Evry, France. More about Nautilus:

http://www.nautilusbiotech.com

About Angel Biotech

Angel Biotech Limited is a research development and contract

manufacturing company specialising in microbial strain development and cGMP

manufacture of recombinant proteins and antibodies in microbial and

mammalian

expressions systems and antibodies. Angel was established in 2001 and has

laboratory and manufacturing facilities in Cramlington, Northumberland,

England and Edinburgh, Scotland. Angel has a highly experienced team

ensuring

that projects are managed quickly and effectively from technical transfer

through process development, scale-up and manufacture to CMC package / IND

submission. Angel has highly developed problem solving capabilities which

are

employed in all projects. Angel is currently significantly expanding its

cGMP

manufacturing capacity in a state of the art multi-product facility. More

about Angel: http://www.angelbio.com

SOURCE Nautilus Biotech

[Guest guest]

Nautilus Biotech and Angel Biothechnology Sign Agreement to Manufacture

Belerofon® (Improved Alpha Interferon) for Phase I Clinical Trials

PARIS, France and NORTHUMBERLAND, England, December 6 /PRNewswire/ --

Nautilus Biotech a protein pharmaceuticals private company and Angel

Biotechnology a UK private company providing world class contract

manufacturing services in microbial fermentation and mammalian cell culture,

announced today that they have signed an agreement for the manufacture of

Nautilus' improved interferon alpha (Belerofon®) for Phase I clinical

development.

Nautilus has designed and developed an improved, single amino-acid

substitution, non-pegylated interferon alpha (Belerofon®) with superior

biological and pharmacological profile compared to marketed pegylated

interferon alpha. Belerofon® is a product candidate for a number of

indications including chronic HepC and cancer. Its improved profile should

support lower frequency of administration and lower dosing with higher

therapeutic efficacy.

" Nautilus is committed to advance Belerofon® into clinical

development.

This agreement for the GMP manufacture of Belerofon® shows our focus to

progressing this product candidate into clinical Phase I " , said Nautilus CEO

Vega. " We believe that in Angel we have found a partner with the

right

blend of experience and facilities to manufacture Belerofon® for the next

steps of our clinical development plan " .

" Nautilus has an impressive track record in the development of new and

improved protein therapeutics " , said Angel CEO Stuart Duncan. " We are

extremely pleased to be working with Nautilus and we are confident that

Angel

can transfer and develop Nautilus manufacturing process and associated

assays

to full cGMP compliance, taking Belerofon® to IND " .

About Belerofon

The market for alpha interferon in the treatment of chronic hepatitis C

infection only, reached $2.7 bn in 2003 and is projected to grow to $8.7 bn

by 2013 and $12.6 bn by 2018. Pegylated derivatives of alpha interferon

dominate the market based on their improved pharmacokinetics profile, which

translates into lower dosing frequency compared to native alpha interferon.

Belerofon® is a single amino acid variant of natural alpha interferon,

engineered by Nautilus, non-pegylated, non-protein fusion. Belerofon® is

an

improved product candidate with longer half-life in serum compared to native

alpha interferon. Belerofon® has a superior pharmacological profile, with

a

half-life in primates equivalent to marketed pegylated alpha interferon

products. The half-life of Belerofon® is expected to support the standard

of care of once per week dosing schedule, currently used for PEG-IFN.

About Nautilus Biotech

Nautilus is focused on improving and developing next generation protein

pharmaceuticals. Using its proprietary and unique technologies, Nautilus has

generated a pipeline of improved therapeutic protein molecules with single

amino acid substitutions; and has IP claims on 20 improved cytokines. Long

lasting interferon alpha and interferon beta, presently in preclinical

development, are Nautilus' lead molecules. Nautilus Biotech is a privately

owned, VC backed company, founded in late 1999 in the frame of the

Genopole® incubator in Evry, France. More about Nautilus:

http://www.nautilusbiotech.com

About Angel Biotech

Angel Biotech Limited is a research development and contract

manufacturing company specialising in microbial strain development and cGMP

manufacture of recombinant proteins and antibodies in microbial and

mammalian

expressions systems and antibodies. Angel was established in 2001 and has

laboratory and manufacturing facilities in Cramlington, Northumberland,

England and Edinburgh, Scotland. Angel has a highly experienced team

ensuring

that projects are managed quickly and effectively from technical transfer

through process development, scale-up and manufacture to CMC package / IND

submission. Angel has highly developed problem solving capabilities which

are

employed in all projects. Angel is currently significantly expanding its

cGMP

manufacturing capacity in a state of the art multi-product facility. More

about Angel: http://www.angelbio.com

SOURCE Nautilus Biotech

[Guest guest]

Nautilus Biotech and Angel Biothechnology Sign Agreement to Manufacture

Belerofon® (Improved Alpha Interferon) for Phase I Clinical Trials

PARIS, France and NORTHUMBERLAND, England, December 6 /PRNewswire/ --

Nautilus Biotech a protein pharmaceuticals private company and Angel

Biotechnology a UK private company providing world class contract

manufacturing services in microbial fermentation and mammalian cell culture,

announced today that they have signed an agreement for the manufacture of

Nautilus' improved interferon alpha (Belerofon®) for Phase I clinical

development.

Nautilus has designed and developed an improved, single amino-acid

substitution, non-pegylated interferon alpha (Belerofon®) with superior

biological and pharmacological profile compared to marketed pegylated

interferon alpha. Belerofon® is a product candidate for a number of

indications including chronic HepC and cancer. Its improved profile should

support lower frequency of administration and lower dosing with higher

therapeutic efficacy.

" Nautilus is committed to advance Belerofon® into clinical

development.

This agreement for the GMP manufacture of Belerofon® shows our focus to

progressing this product candidate into clinical Phase I " , said Nautilus CEO

Vega. " We believe that in Angel we have found a partner with the

right

blend of experience and facilities to manufacture Belerofon® for the next

steps of our clinical development plan " .

" Nautilus has an impressive track record in the development of new and

improved protein therapeutics " , said Angel CEO Stuart Duncan. " We are

extremely pleased to be working with Nautilus and we are confident that

Angel

can transfer and develop Nautilus manufacturing process and associated

assays

to full cGMP compliance, taking Belerofon® to IND " .

About Belerofon

The market for alpha interferon in the treatment of chronic hepatitis C

infection only, reached $2.7 bn in 2003 and is projected to grow to $8.7 bn

by 2013 and $12.6 bn by 2018. Pegylated derivatives of alpha interferon

dominate the market based on their improved pharmacokinetics profile, which

translates into lower dosing frequency compared to native alpha interferon.

Belerofon® is a single amino acid variant of natural alpha interferon,

engineered by Nautilus, non-pegylated, non-protein fusion. Belerofon® is

an

improved product candidate with longer half-life in serum compared to native

alpha interferon. Belerofon® has a superior pharmacological profile, with

a

half-life in primates equivalent to marketed pegylated alpha interferon

products. The half-life of Belerofon® is expected to support the standard

of care of once per week dosing schedule, currently used for PEG-IFN.

About Nautilus Biotech

Nautilus is focused on improving and developing next generation protein

pharmaceuticals. Using its proprietary and unique technologies, Nautilus has

generated a pipeline of improved therapeutic protein molecules with single

amino acid substitutions; and has IP claims on 20 improved cytokines. Long

lasting interferon alpha and interferon beta, presently in preclinical

development, are Nautilus' lead molecules. Nautilus Biotech is a privately

owned, VC backed company, founded in late 1999 in the frame of the

Genopole® incubator in Evry, France. More about Nautilus:

http://www.nautilusbiotech.com

About Angel Biotech

Angel Biotech Limited is a research development and contract

manufacturing company specialising in microbial strain development and cGMP

manufacture of recombinant proteins and antibodies in microbial and

mammalian

expressions systems and antibodies. Angel was established in 2001 and has

laboratory and manufacturing facilities in Cramlington, Northumberland,

England and Edinburgh, Scotland. Angel has a highly experienced team

ensuring

that projects are managed quickly and effectively from technical transfer

through process development, scale-up and manufacture to CMC package / IND

submission. Angel has highly developed problem solving capabilities which

are

employed in all projects. Angel is currently significantly expanding its

cGMP

manufacturing capacity in a state of the art multi-product facility. More

about Angel: http://www.angelbio.com

SOURCE Nautilus Biotech

[Guest guest]

Nautilus Biotech and Angel Biothechnology Sign Agreement to Manufacture

Belerofon® (Improved Alpha Interferon) for Phase I Clinical Trials

PARIS, France and NORTHUMBERLAND, England, December 6 /PRNewswire/ --

Nautilus Biotech a protein pharmaceuticals private company and Angel

Biotechnology a UK private company providing world class contract

manufacturing services in microbial fermentation and mammalian cell culture,

announced today that they have signed an agreement for the manufacture of

Nautilus' improved interferon alpha (Belerofon®) for Phase I clinical

development.

Nautilus has designed and developed an improved, single amino-acid

substitution, non-pegylated interferon alpha (Belerofon®) with superior

biological and pharmacological profile compared to marketed pegylated

interferon alpha. Belerofon® is a product candidate for a number of

indications including chronic HepC and cancer. Its improved profile should

support lower frequency of administration and lower dosing with higher

therapeutic efficacy.

" Nautilus is committed to advance Belerofon® into clinical

development.

This agreement for the GMP manufacture of Belerofon® shows our focus to

progressing this product candidate into clinical Phase I " , said Nautilus CEO

Vega. " We believe that in Angel we have found a partner with the

right

blend of experience and facilities to manufacture Belerofon® for the next

steps of our clinical development plan " .

" Nautilus has an impressive track record in the development of new and

improved protein therapeutics " , said Angel CEO Stuart Duncan. " We are

extremely pleased to be working with Nautilus and we are confident that

Angel

can transfer and develop Nautilus manufacturing process and associated

assays

to full cGMP compliance, taking Belerofon® to IND " .

About Belerofon

The market for alpha interferon in the treatment of chronic hepatitis C

infection only, reached $2.7 bn in 2003 and is projected to grow to $8.7 bn

by 2013 and $12.6 bn by 2018. Pegylated derivatives of alpha interferon

dominate the market based on their improved pharmacokinetics profile, which

translates into lower dosing frequency compared to native alpha interferon.

Belerofon® is a single amino acid variant of natural alpha interferon,

engineered by Nautilus, non-pegylated, non-protein fusion. Belerofon® is

an

improved product candidate with longer half-life in serum compared to native

alpha interferon. Belerofon® has a superior pharmacological profile, with

a

half-life in primates equivalent to marketed pegylated alpha interferon

products. The half-life of Belerofon® is expected to support the standard

of care of once per week dosing schedule, currently used for PEG-IFN.

About Nautilus Biotech

Nautilus is focused on improving and developing next generation protein

pharmaceuticals. Using its proprietary and unique technologies, Nautilus has

generated a pipeline of improved therapeutic protein molecules with single

amino acid substitutions; and has IP claims on 20 improved cytokines. Long

lasting interferon alpha and interferon beta, presently in preclinical

development, are Nautilus' lead molecules. Nautilus Biotech is a privately

owned, VC backed company, founded in late 1999 in the frame of the

Genopole® incubator in Evry, France. More about Nautilus:

http://www.nautilusbiotech.com

About Angel Biotech

Angel Biotech Limited is a research development and contract

manufacturing company specialising in microbial strain development and cGMP

manufacture of recombinant proteins and antibodies in microbial and

mammalian

expressions systems and antibodies. Angel was established in 2001 and has

laboratory and manufacturing facilities in Cramlington, Northumberland,

England and Edinburgh, Scotland. Angel has a highly experienced team

ensuring

that projects are managed quickly and effectively from technical transfer

through process development, scale-up and manufacture to CMC package / IND

submission. Angel has highly developed problem solving capabilities which

are

employed in all projects. Angel is currently significantly expanding its

cGMP

manufacturing capacity in a state of the art multi-product facility. More

about Angel: http://www.angelbio.com

SOURCE Nautilus Biotech